An Iowa drug developer is preparing to test a possible Ebola vaccine in humans, as scientists race to develop ways to prevent or fight a virus that has killed more than 1,000 people in a West African outbreak.
NewLink Genetics is planning an initial phase of testing involving up to 100 healthy volunteers and is talking with regulators about the study, said Brian Wiley, the company’s vice president for business development. He declined to say whether the drug developer has submitted an application for the research to the Food and Drug Administration.
Chief Financial Officer Gordon Link said Thursday the timing of the testing, which would involve up to 100 healthy volunteers, is uncertain.
“We’re getting a lot of assistance from a number of sources to accelerate this, so exactly how long it’s going to take is a little uncertain because people are greasing the paths as much as they can,” he said.
In addition to the research, NewLink also plans to make between 800 and 1,000 doses of the vaccine that the Canadian government will donate to the World Health Organization, which is coordinating the international response to the latest outbreak. Scientists from Canada’s public health agency developed the vaccine and licensed it to NewLink.
There is no proven treatment or vaccine for Ebola, and the current outbreak, which also has sickened nearly 2,000 people, is the largest in history. The outbreak was first detected in March in Guinea and spread to Liberia, Sierra Leone and Nigeria.
Other possible Ebola vaccines under development include one developed at the National Institutes of Health that is set to begin early-stage testing in humans this fall. On Wednesday, Canadian drugmaker Tekmira Pharmaceuticals Corp. said it wasn’t ready to make its experimental Ebola drug available in Africa.
NewLink Genetics Corp. said its vaccine has been 100 percent effective in preventing deadly Ebola infections in non-human primates, and it acts quickly enough to show effectiveness in animals that received a typically lethal dose of the virus.The vaccine contains an antigen from the Ebola virus, and it essentially teaches a person’s immune system how to fight the virus.
“This is a very traditional vaccination process,” said Dr. Nicholas Vahanian, NewLink’s chief medical officer […]
READ FULL STORY
Date: August 14, 2014
Source: Associated AP Business Writer Tom Murphy,
SUBSCRIBE TO OUR BLOG IN THE RIGHT SIDEBAR MENU TO RECEIVE OUR DAILY BLOG POST DIRECTLY TO YOUR E-MAIL
SUBSCRIBE TO OUR NEWSLETTER TO RECEIVE A MONTHLY MAIL WITH MORE RELEVANT INDUSTRY AND COMPANY NEWS
Add a Comment